ClinicalTrials.gg
CompletedNCT02465606Updated Jan 27, 2020

A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis

A Phase 2 interventional study of Lebrikizumab and Topical Corticosteroid Creams (Triamcinolone acetonide 0.1% and Hydrocortisone 2.5%) in Atopic Dermatitis, sponsored by Hoffmann-La Roche. Completed at 19 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-01-27.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
55
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing lebrikizumab in Dermatitis, Atopic — 4 open to participants now, 7 under way, 4 of them phase 3. lebrikizumab · Dermatitis, Atopic.

Enrollment
22nd of 24
55 · median 252
Started
2015
with 1 other
Phase 2
3 of 24
none open now
Registered
2nd of 24
by date
Lead sponsor
2 of 24
Hoffmann-La Roche

Among the 24 studies testing lebrikizumab in Dermatitis, Atopic, this one is the 22nd largest by enrollment, is one of 2 that started in 2015, is one of 3 in phase 2, and was the 2nd registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

4 of the 24 studies testing lebrikizumab in Dermatitis, Atopic are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About lebrikizumab

lebrikizumab: first FDA approval 2024 (EBGLYSS), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing lebrikizumab in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The primary objective for this study is to evaluate the safety of lebrikizumab compared with Topical Corticosteroids (TCS) alone in patients with persistent moderate to severe Atopic Dermatitis (AD) that is inadequately controlled with TCS.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 75 years, inclusive, at the start of the run-in period
  • AD diagnosed by the Hanifin/Rajka criteria and that has been present for at least 1 year at screening
  • Moderate to severe AD as graded by the Rajka/Langeland criteria at screening
  • History of inadequate response to a >/= 1 month (within the 3 months prior to the screening visit) treatment regimen of at least daily TCS and regular emollient for treatment of AD
  • EASI score >/= 14 at screening
  • IGA score >/= 3
  • AD involvement of >/= 10% body surface area
  • Pruritus Visual Analog Scale score >/= 3

Exclusion criteria

Exclusion Criteria:

  • Past and/or current use of any anti-IL-13 or anti-IL-4/IL-13 therapy, including lebrikizumab
  • Use of an agent within 4 weeks prior to screening or within 5 half-lives of the investigational agent, whichever is longer
  • Evidence of other skin conditions, including, but not limited to, T-cell lymphoma or allergic contact dermatitis
  • History of a severe allergic reaction or anaphylactic reaction to a biologic agent or known to any component of the lebrikizumab injection
  • Use of any complementary, alternative, or homeopathic medicines including, but not limited to, phytotherapies, traditional or non-traditional herbal medications, essential fatty acids, or acupuncture within 7 days prior to the run-in period or need for such medications during the study
  • Evidence of other skin conditions; including, but not limited to, T-cell lymphoma or allergic contact dermatitis
  • Evidence of, or ongoing treatment (including topical antibiotics) for active skin infection at screening
  • Other recent infections meeting protocol criteria
  • Active tuberculosis requiring treatment within the 12 months prior to Visit 1
  • Evidence of acute or chronic hepatitis or known liver cirrhosis
  • Known immunodeficiency, including infection
  • Use of a topical calcineurin inhibitor (TCI) at the time of screening, unless the patient is willing to stop TCI use during the study (including the run-in period) and, in the investigator's opinion, it is safe to do so
  • abnormality on screening or laboratory tests
  • Known current or current evaluation for a potential malignancy, including basal or squamous cell carcinoma of the skin or carcinoma in situ
  • History of malignancy within 5 years prior to screening, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine cancer
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    Group 1: Lebrikizumab Dose Level 1 Monotherapy

    During the 2-week run-in period, participants will receive topical corticosteroid creams to be self-applied two times per day to active skin lesions only. During the 12-week treatment period, lebrikizumab monotherapy will be administered by subcutaneous (SC) injection, but participants assigned to this group will not receive topical corticosteroids. During the 8-week safety follow-up period, all participants will receive topical corticosteroids to be self-applied to active skin lesions as decided by the participant and study investigator.

    Drug: Lebrikizumab · Drug: Topical Corticosteroid Creams (Triamcinolone acetonide 0.1% and Hydrocortisone 2.5%)

  • Active comparator
    Group 2: Topical Corticosteroid Creams Only

    During the 2-week run-in period and during the 12-week treatment period, participants assigned to this group will receive topical corticosteroid creams to be self-applied two times per day to active skin lesions only. During the 8-week safety follow-up period, all participants will receive topical corticosteroids to be self-applied to active skin lesions as decided by the participant and study investigator.

    Drug: Topical Corticosteroid Creams (Triamcinolone acetonide 0.1% and Hydrocortisone 2.5%)

Interventions

  • Lebrikizumab Dose Level 1 subcutaneous monotherapy was administered SC once every 4 weeks for a total of 3 doses.

  • DrugTopical Corticosteroid Creams (Triamcinolone acetonide 0.1% and Hydrocortisone 2.5%)

    Drug page: Triamcinolone Acetonide

    Triamcinolone acetonide 0.1% cream will be supplied as single 454-g jars to be used on the body. Hydrocortisone 2.5% cream will be supplied as single 28-g tubes to be used on the face and intertriginous areas as indicated.

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment-emergent adverse events (TEAEs)

    Time frame: From baseline to week 12

Secondary outcomes

  1. Immunogenicity: Percentage of participants with anti-Lebrikizumab antibodies

    Time frame: From baseline to week 20

  2. Number of participants with disease rebound following discontinuation of study drug

    Time frame: within 20 weeks

  3. Serum lebrikizumab concentration at Week 12

    Time frame: Week 12

  4. Elimination half-life

    Time frame: Week 4

  5. Number of participants with skin and other organ system infections

    Time frame: From baseline to week 12

  6. Number of participants with injection site reactions

    Time frame: From baseline to week 12

07

Study locations

19 sites
  • T. Joseph Raoof Md, Inc.
    Encino, California 91436, United States
  • Allergy and Asthma Relief Experts
    Granada Hills, California 91344, United States
  • Allergy and Asthma Associates of Southern California - CRN
    Mission Viejo, California 92691, United States
  • Forward Clinical Trials
    Tampa, Florida 33624, United States
  • Dermatology Specialists Research, LLC
    Louisville, Kentucky 40241, United States
  • Respiratory Medicine Research; Institue of Michigan P.L.C.
    Ypsilanti, Michigan 48197, United States
  • Montefiore Medical Center
    Bronx, New York 10467, United States
  • Sadick Research Group
    New York, New York 10075, United States
  • Oregon Medical Research Center
    Portland, Oregon 97223, United States
  • Temple University Hospital
    Philadelphia, Pennsylvania 19140, United States
  • Asthma & Allergy Physicians of Rhode Island Clinical Research Institute (AAPRI CRI)
    Warwick, Rhode Island 02865, United States
  • Center for Clinical Studies
    Cypress, Texas 77433, United States
  • Dr. Lorne E. Albrecht Inc.
    Surrey, British Columbia V3R 6A7, Canada
  • Skin Care Centre
    Vancouver, British Columbia V5Z 4E8, Canada
  • Wiseman Dermatology Research Inc.
    Winnipeg, Manitoba R3M 3Z4, Canada
  • Guenther Research Inc.
    London, Ontario N6A 3H7, Canada
  • The Centre for Clinical Trials Inc.
    Oakville, Ontario L6J 7W5, Canada
  • York Dermatology Center
    Richmond Hill, Ontario L4C 9M7, Canada
  • K. Papp Clinical Research Inc.
    Waterloo, Ontario N2J 1C4, Canada
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2015 to primary completion in May 2016, 10 months.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 10 months is below that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2015
First posted
Jun 8, 2015
StartActual
Jul 30, 2015
Primary completionActual
May 30, 2016
CompletionActual
May 30, 2016
Results delay requested
Jan 17, 2020
Last update
Jan 27, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02465606
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 8, 2015
Start date
Jul 30, 2015
Primary completion
May 30, 2016
Completion
May 30, 2016
Last update
Jan 27, 2020

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lebrikizumab

Start the discussion